Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1

Bandana Chatterjee, Ibtissam Echchgadda, Chung-seog Song

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

SULT2A1 is a sulfo-conjugating phase II enzyme expressed at very high levels in the liver and intestine, the two major first-pass metabolic tissues, and in the steroidogenic adrenal tissue. SULT2A1 acts preferentially on the hydroxysteroids dehydroepiandrosterone, testosterone/dihydrotestosterone, and pregnenolone and on cholesterol-derived amphipathic sterol bile acids. Several therapeutic drugs and other xenobiotics, which include xenoestrogens, are also sulfonated by this cytosolic steroid/bile acid sulfotransferase. Nonsteroid nuclear receptors with key roles in the metabolism and detoxification of endobiotics and xenobiotics, such as bile acid-activated farnesoid X receptor, xenobiotic-activated pregnane X receptor and constitutive androstane receptor, and lipid-activated peroxisome proliferator-activated receptor-α, mediate transcription induction of SULT2A1 in the enterohepatic system. The ligand-activated vitamin D receptor (VDR) is another nuclear receptor that stimulates SULT2A1 transcription, and the regulatory elements in human, mouse, and rat promoters directing this induction have been characterized. Given that bile acid sulfonation is catalyzed exclusively by SULT2A1 and that the 3α-sulfate of the highly toxic lithocholic acid is a major excretory metabolite in humans, we speculate that a role for the VDR pathway in SULT2A1 expression may have emerged to shield first-pass tissues from the cytotoxic effects of a bile acid overload arising from disrupted sterol homeostasis triggered by endogenous and exogenous factors.

Original languageEnglish (US)
Article number10
Pages (from-to)165-191
Number of pages27
JournalMethods in Enzymology
Volume400
DOIs
StatePublished - 2005

Fingerprint

Calcitriol Receptors
Bile Acids and Salts
Xenobiotics
Steroids
Sterols
Transcription
Tissue
Cytoplasmic and Nuclear Receptors
Lithocholic Acid
Hydroxysteroids
Pregnenolone
Detoxification
Sulfonation
Peroxisome Proliferator-Activated Receptors
Dehydroepiandrosterone
Dihydrotestosterone
Poisons
Metabolites
Metabolism
Liver

ASJC Scopus subject areas

  • Biochemistry

Cite this

Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. / Chatterjee, Bandana; Echchgadda, Ibtissam; Song, Chung-seog.

In: Methods in Enzymology, Vol. 400, 10, 2005, p. 165-191.

Research output: Contribution to journalArticle

Chatterjee, Bandana ; Echchgadda, Ibtissam ; Song, Chung-seog. / Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. In: Methods in Enzymology. 2005 ; Vol. 400. pp. 165-191.
@article{86305d52bf26435eb2ddd09bddecdb09,
title = "Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1",
abstract = "SULT2A1 is a sulfo-conjugating phase II enzyme expressed at very high levels in the liver and intestine, the two major first-pass metabolic tissues, and in the steroidogenic adrenal tissue. SULT2A1 acts preferentially on the hydroxysteroids dehydroepiandrosterone, testosterone/dihydrotestosterone, and pregnenolone and on cholesterol-derived amphipathic sterol bile acids. Several therapeutic drugs and other xenobiotics, which include xenoestrogens, are also sulfonated by this cytosolic steroid/bile acid sulfotransferase. Nonsteroid nuclear receptors with key roles in the metabolism and detoxification of endobiotics and xenobiotics, such as bile acid-activated farnesoid X receptor, xenobiotic-activated pregnane X receptor and constitutive androstane receptor, and lipid-activated peroxisome proliferator-activated receptor-α, mediate transcription induction of SULT2A1 in the enterohepatic system. The ligand-activated vitamin D receptor (VDR) is another nuclear receptor that stimulates SULT2A1 transcription, and the regulatory elements in human, mouse, and rat promoters directing this induction have been characterized. Given that bile acid sulfonation is catalyzed exclusively by SULT2A1 and that the 3α-sulfate of the highly toxic lithocholic acid is a major excretory metabolite in humans, we speculate that a role for the VDR pathway in SULT2A1 expression may have emerged to shield first-pass tissues from the cytotoxic effects of a bile acid overload arising from disrupted sterol homeostasis triggered by endogenous and exogenous factors.",
author = "Bandana Chatterjee and Ibtissam Echchgadda and Chung-seog Song",
year = "2005",
doi = "10.1016/S0076-6879(05)00010-8",
language = "English (US)",
volume = "400",
pages = "165--191",
journal = "Methods",
issn = "0076-6879",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1

AU - Chatterjee, Bandana

AU - Echchgadda, Ibtissam

AU - Song, Chung-seog

PY - 2005

Y1 - 2005

N2 - SULT2A1 is a sulfo-conjugating phase II enzyme expressed at very high levels in the liver and intestine, the two major first-pass metabolic tissues, and in the steroidogenic adrenal tissue. SULT2A1 acts preferentially on the hydroxysteroids dehydroepiandrosterone, testosterone/dihydrotestosterone, and pregnenolone and on cholesterol-derived amphipathic sterol bile acids. Several therapeutic drugs and other xenobiotics, which include xenoestrogens, are also sulfonated by this cytosolic steroid/bile acid sulfotransferase. Nonsteroid nuclear receptors with key roles in the metabolism and detoxification of endobiotics and xenobiotics, such as bile acid-activated farnesoid X receptor, xenobiotic-activated pregnane X receptor and constitutive androstane receptor, and lipid-activated peroxisome proliferator-activated receptor-α, mediate transcription induction of SULT2A1 in the enterohepatic system. The ligand-activated vitamin D receptor (VDR) is another nuclear receptor that stimulates SULT2A1 transcription, and the regulatory elements in human, mouse, and rat promoters directing this induction have been characterized. Given that bile acid sulfonation is catalyzed exclusively by SULT2A1 and that the 3α-sulfate of the highly toxic lithocholic acid is a major excretory metabolite in humans, we speculate that a role for the VDR pathway in SULT2A1 expression may have emerged to shield first-pass tissues from the cytotoxic effects of a bile acid overload arising from disrupted sterol homeostasis triggered by endogenous and exogenous factors.

AB - SULT2A1 is a sulfo-conjugating phase II enzyme expressed at very high levels in the liver and intestine, the two major first-pass metabolic tissues, and in the steroidogenic adrenal tissue. SULT2A1 acts preferentially on the hydroxysteroids dehydroepiandrosterone, testosterone/dihydrotestosterone, and pregnenolone and on cholesterol-derived amphipathic sterol bile acids. Several therapeutic drugs and other xenobiotics, which include xenoestrogens, are also sulfonated by this cytosolic steroid/bile acid sulfotransferase. Nonsteroid nuclear receptors with key roles in the metabolism and detoxification of endobiotics and xenobiotics, such as bile acid-activated farnesoid X receptor, xenobiotic-activated pregnane X receptor and constitutive androstane receptor, and lipid-activated peroxisome proliferator-activated receptor-α, mediate transcription induction of SULT2A1 in the enterohepatic system. The ligand-activated vitamin D receptor (VDR) is another nuclear receptor that stimulates SULT2A1 transcription, and the regulatory elements in human, mouse, and rat promoters directing this induction have been characterized. Given that bile acid sulfonation is catalyzed exclusively by SULT2A1 and that the 3α-sulfate of the highly toxic lithocholic acid is a major excretory metabolite in humans, we speculate that a role for the VDR pathway in SULT2A1 expression may have emerged to shield first-pass tissues from the cytotoxic effects of a bile acid overload arising from disrupted sterol homeostasis triggered by endogenous and exogenous factors.

UR - http://www.scopus.com/inward/record.url?scp=30144431977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30144431977&partnerID=8YFLogxK

U2 - 10.1016/S0076-6879(05)00010-8

DO - 10.1016/S0076-6879(05)00010-8

M3 - Article

C2 - 16399349

AN - SCOPUS:30144431977

VL - 400

SP - 165

EP - 191

JO - Methods

JF - Methods

SN - 0076-6879

M1 - 10

ER -